Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients

Autoimmunity Reviews

Volumn 14, Issue 10, 2015, Pages 903-913

  Fitzner, Brit ^a,b   Hecker, Michael ^a,b   Zettl, Uwe Klaus ^b  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b STZ for Proteome Analysis   (Germany)

Author keywords

Cerebrospinal fluid; Diagnosis; Molecular biomarker; Monitoring; Multiple sclerosis; Prognosis

Indexed keywords

ANTIBODY; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CXCL13 CHEMOKINE; DNA; FETUIN A; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; RANTES; SELECTIN; STRUCTURAL PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4; BIOLOGICAL MARKER; CYTOKINE;

CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; DISEASE COURSE; HUMAN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRACTICE GUIDELINE; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; TREATMENT RESPONSE; ANIMAL; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; IMMUNOLOGY; PROGNOSIS;

ANIMALS; ANTIBODIES; BIOMARKERS; BLOOD-BRAIN BARRIER; CYTOKINES; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 84940614375     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.06.001     Document Type: Review

References (144)

1. Oreja-Guevara C., Wiendl H., Kieseier B.C., Airas L. Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Ther Adv Neurol Disord 2014, 7:137-149.
2. Milo R., Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014, 13:518-524.
3. Stadelmann C., Wegner C., Brück W. Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta 1812, 2011:275-282.
4. Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S., Thompson A.J., et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014, 83:278-286.
5. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
6. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
7. Gajofatto A., Calabrese M., Benedetti M.D., Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013, 35:687-699.
8. Katz Sand I.B., Lublin F.D. Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn) 2013, 19:922-943.
9. Tumani H., Deisenhammer F., Giovannoni G., Gold R., Hartung H.-P., Hemmer B., et al. Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011, 70:520. [author reply 521].
10. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
11. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
12. Engelhardt B., Ransohoff R.M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012, 33:579-589.
13. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
14. Teunissen C.E., Tumani H., Bennett J.L., Berven F.S., Brundin L., Comabella M., et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011, 2011:246412.
15. Teunissen C.E., Menge T., Altintas A., Álvarez-Cermeño J.C., Bertolotto A., Berven F.S., et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013, 19:1802-1809.
16. Giovannoni G., Nath A. After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 2011, 76:1200-1201.
17. Tumani H., Hartung H.-P., Hemmer B., Teunissen C.E., Deisenhammer F., Giovannoni G., et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009, 35:117-127.
18. Harris V.K., Sadiq S.A. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009, 13:225-244.
19. Katsavos S., Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. Mult Scler Int 2013, 2013:340508.
20. Ziemann U., Wahl M., Hattingen E., Tumani H. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol 2011, 95:670-685.
21. Reiber H., Peter J.B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001, 184:101-122.
22. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 2006, 22:235-244.
23. Link H., Huang Y.-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006, 180:17-28.
24. Zettl U.K., Tumani H. Multiple sclerosis & cerebrospinal fluid 2005, Blackwell Publishing LtD, Oxford. 1st ed.
25. Dobson R., Ramagopalan S., Davis A., Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013, 84:909-914.
26. Sellebjerg F., Jensen C.V., Christiansen M. Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis. J Neuroimmunol 2000, 108:207-215.
27. Perini P., Ranzato F., Calabrese M., Battistin L., Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006, 77:953-955.
28. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002, 58:824-826.
29. Mandrioli J., Sola P., Bedin R., Gambini M., Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008, 255:1023-1031.
30. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002, 59:555-559.
31. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003, 53:222-226.
32. Schneider R., Euler B., Rauer S. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol 2007, 14:907-911.
33. Arneth B., Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009, 119:39-44.
34. Goffette S., Schluep M., Henry H., Duprez T., Sindic C.J.M. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry 2004, 75:308-310.
35. Presslauer S., Milosavljevic D., Brücke T., Bayer P., Hübl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008, 255:1508-1514.
36. Rinker J.R., Trinkaus K., Cross A.H. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006, 67:1288-1290.
37. Bartos A., Fialová L., Soukupová J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007, 254:20-25.
38. Eikelenboom M.J., Petzold A., Lazeron R.H.C., Silber E., Sharief M., Thompson E.J., et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60:219-223.
39. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
40. Bartos A., Fialová L., Soukupová J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007, 116:100-107.
41. Fialová L., Bartos A., Svarcová J., Zimova D., Kotoucova J., Malbohan I. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol 2013, 262:113-120.
42. Sueoka E., Yukitake M., Iwanaga K., Sueoka N., Aihara T., Kuroda Y. Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann Neurol 2004, 56:778-786.
43. Yukitake M., Sueoka E., Sueoka-Aragane N., Sato A., Ohashi H., Yakushiji Y., et al. Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2008, 14:130-135.
44. Fraussen J., Claes N., de Bock L., Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014, 13:1126-1137.
45. Garren H., Robinson W.H., Krasulová E., Havrdová E., Nadj C., Selmaj K., et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008, 63:611-620.
46. Bar-Or A., Vollmer T., Antel J., Arnold D.L., Bodner C.A., Campagnolo D., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007, 64:1407-1415.
47. Lalive P.H., Menge T., Delarasse C., Della Gaspera B., Pham-Dinh D., Villoslada P., et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:2280-2285.
48. Reindl M., Di Pauli F., Rostásy K., Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9:455-461.
49. Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Brück W., et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:19057-19062.
50. Di Pauli F., Mader S., Rostasy K., Schanda K., Bajer-Kornek B., Ehling R., et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011, 138:247-254.
51. Guggenmos J., Schubart A.S., Ogg S., Andersson M., Olsson T., Mather I.H., et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol 2004, 172:661-668.
52. Hecker M., Fitzner B., Lorenz P., Flechtner K., Steinbeck F., Schröder I., et al. High-density peptide microarray analysis of IgG autoantibody reactivities in serum and cerebrospinal fluid of multiple sclerosis patients 2015, [submitted for publication].
53. Chiba S., Yokota S., Yonekura K., Tanaka S., Furuyama H., Kubota H., et al. Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J Neurol Sci 2006, 241:39-43.
54. Jarius S., Franciotta D., Paul F., Ruprecht K., Bergamaschi R., Rommer P.S., et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010, 7:52.
55. Long Y., Qiu W., Lu Z., Bao J., Wu A., Wang Y., et al. Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation 2012, 19:96-102.
56. Srivastava R., Aslam M., Kalluri S.R., Schirmer L., Buck D., Tackenberg B., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
57. Schirmer L., Srivastava R., Kalluri S.R., Böttinger S., Herwerth M., Carassiti D., et al. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol 2014, 75:810-828.
58. Wunsch M., Rovituso D.M., Kuerten S. KIR4.1 antibodies as biomarkers in multiple sclerosis. Front Neurol 2014, 5:62.
59. Nerrant E., Salsac C., Charif M., Ayrignac X., Carra-Dalliere C., Castelnovo G., et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 2014, 20:1699-1703.
60. Brickshawana A., Hinson S.R., Romero M.F., Lucchinetti C.F., Guo Y., Buttmann M., et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2014, 13:795-806.
61. Owens G.P., Gilden D., Burgoon M.P., Yu X., Bennett J.L. Viruses and multiple sclerosis. Neuroscience 2011, 17:659-676.
62. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Büssow K., et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005, 115:1352-1360.
63. Lindsey J.W., Khan U., Ansari W., Powell T., Wang Y.H., Guirguis M.S. The antibody response to Epstein-Barr virions is altered in multiple sclerosis. J Neuroimmunol 2013, 254:146-153.
64. Virtanen J.O., Pietiläinen-Nicklén J., Uotila L., Färkkilä M., Vaheri A., Koskiniemi M. Intrathecal human herpes virus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid. J Neuroimmunol 2011, 237:93-97.
65. Virtanen J.O., Färkkilä M., Multanen J., Uotila L., Jääskeläinen A.J., Vaheri A., et al. Evidence for human herpes virus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications. J Neurovirol 2007, 13:347-352.
66. Derfuss T., Hohlfeld R., Meinl E. Intrathecal antibody (IgG) production against human herpes virus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol 2005, 252:968-971.
67. Brecht I., Weissbrich B., Braun J., Toyka K.V., Weishaupt A., Buttmann M. Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. PLoS One 2012, 7:e40431.
68. Ahlgren C., Odén A., Bergström T., Lycke J. Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome. J Neuroimmunol 2012, 247:70-74. 10.1016/j.jneuroim.2012.03.014.
69. Sundqvist E., Sundström P., Lindén M., Hedström a K., Aloisi F., Hillert J., et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012, 13:14-20. 10.1038/gene.2011.42.
70. Lin J., Bettin P., Lee J.K., Ho J.K., Sadiq S.A. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. J Neuroimmunol 2013, 261:123-128.
71. Warnke C., von Geldern G., Markwerth P., Dehmel T., Hoepner R., Gold R., et al. The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol 2014, 76:792-801.
72. Khademi M., Kockum I., Andersson M.L., Iacobaeus E., Brundin L., Sellebjerg F., et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011, 17:335-343.
73. Harris V.K., Sadiq S.A. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther 2014, 18:605-617.
74. Axelsson M., Malmeström C., Gunnarsson M., Zetterberg H., Sundström P., Lycke J., et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014, 20:43-50.
75. Chen S.-J., Wang Y.-L., Fan H.-C., Lo W.-T., Wang C.-C., Sytwu H.-K. Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012, 2012:970789.
76. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
77. Cao Y., Goods B.A., Raddassi K., Nepom G.T., Kwok W.W., Love J.C., et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med 2015, 7:287ra74.
78. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
79. Duan H., Luo Y., Hao H., Feng L., Zhang Y., Lu D., et al. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis. Neuroscience 2013, 235:16-26.
80. Edwards L.J., Sharrack B., Ismail A., Tumani H., Constantinescu C.S. Central inflammation versus peripheral regulation in multiple sclerosis. J Neurol 2011, 258:1518-1527.
81. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
82. Graber J.J., Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 2011, 305:1-10.
83. Malmeström C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61:1720-1725.
84. Teunissen C.E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M.J.A., et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009, 72:1322-1329.
85. Salzer J., Svenningsson A., Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010, 16:287-292.
86. Kuhle J., Malmeström C., Axelsson M., Plattner K., Yaldizli Ö., Derfuss T., et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013, 128:e33-e36.
87. Kuhle J., Disanto G., Lorscheider J., Stites T., Chen Y., Dahlke F., et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015, 84:1639-1643.
88. Teunissen C.E., Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012, 18:552-556.
89. Takano R., Misu T., Takahashi T., Sato S., Fujihara K., Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010, 75:208-216.
90. Axelsson M., Malmeström C., Nilsson S., Haghighi S., Rosengren L., Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 2011, 258:882-888.
91. Lehmensiek V., Süssmuth S.D., Tauscher G., Brettschneider J., Felk S., Gillardon F., et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007, 13:840-849.
92. Ottervald J., Franzén B., Nilsson K., Andersson L.I., Khademi M., Eriksson B., et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010, 73:1117-1132.
93. Harris V.K., Donelan N., Yan Q.J., Clark K., Touray A., Rammal M., et al. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler 2013, 19:1462-1472.
94. Tumani H., Lehmensiek V., Rau D., Guttmann I., Tauscher G., Mogel H., et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009, 452:214-217.
95. Bartosik-Psujek H., Archelos J.J. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004, 251:414-420.
96. Martínez-Yélamos A., Rovira A., Sánchez-Valle R., Martínez-Yélamos S., Tintoré M., Blanco Y., et al. CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol 2004, 251:1278-1279.
97. Martínez-Yélamos A., Saiz A., Sanchez-Valle R., Casado V., Ramón J.M., Graus F., et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001, 57:722-724.
98. Romme Christensen J., Börnsen L., Hesse D., Krakauer M., Sørensen P.S., Søndergaard H.B., et al. Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. J Neuroinflammation 2012, 9:215.
99. Trentini A., Comabella M., Tintoré M., Koel-Simmelink M.J.A., Killestein J., Roos B., et al. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014, 261:2338-2343.
100. Greco A., Minghetti L., Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000, 25:1357-1364.
101. Correale J., de los Milagros Bassani Molinas M. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003, 140:198-209.
102. Acar G., Idiman F., Kirkali G., Ozakbaş S., Oktay G., Cakmakçi H., et al. Intrathecal sICAM-1 production in multiple sclerosis-correlation with triple dose Gd-DTPA MRI enhancement and IgG index. J Neurol 2005, 252:146-150.
103. Uzawa A., Mori M., Masuda S., Kuwabara S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011, 68:913-917.
104. Harris V.K., Diamanduros A., Good P., Zakin E., Chalivendra V., Sadiq S.A. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 2010, 40:331-339.
105. Prakash M., Bodas M., Prakash D., Nawani N., Khetmalas M., Mandal A., et al. Diverse pathological implications of YKL-40: answers may lie in "outside-in" signaling. Cell Signal 2013, 25:1567-1573.
106. Bonneh-Barkay D., Wang G., Starkey A., Hamilton R.L., Wiley C.A. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010, 7:34.
107. Correale J., Fiol M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 2011, 17:521-531.
108. Malmeström C., Axelsson M., Lycke J., Zetterberg H., Blennow K., Olsson B. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol 2014, 269:87-89.
109. Comabella M., Fernández M., Martin R., Rivera-Vallvé S., Borrás E., Chiva C., et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133:1082-1093.
110. Stoop M.P., Singh V., Stingl C., Martin R., Khademi M., Olsson T., et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res 2013, 12:1101-1107.
111. Yu X., Kasprick A., Petersen F. Revisiting the role of mast cells in autoimmunity. Autoimmun Rev 2015, 14:751-759.
112. Brynedal B., Khademi M., Wallström E., Hillert J., Olsson T., Duvefelt K. Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery?. Neurobiol Dis 2010, 37:613-621.
113. Matusevicius D., Kivisäkk P., He B., Kostulas N., Özenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
114. Khademi M., Bornsen L., Rafatnia F., Andersson M., Brundin L., Piehl F., et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009, 16:528-536.
115. Muraro P.A., Cassiani-Ingoni R., Chung K., Packer A.N., Sospedra M., Martin R. Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis. J Neuroimmunol 2006, 171:177-183.
116. Warnke C., Mausberg A.K., Stettner M., Dehmel T., Nekrich L., Horste G.M.Z., et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013, 81:1400-1408.
117. Matsumoto Y., Yoon W.K., Jee Y., Fujihara K., Misu T., Sato S., et al. Complementarity-determining region 3 spectra typing analysis of the TCR repertoire in multiple sclerosis. J Immunol 2003, 170:4846-4853.
118. Haghikia A., Hellwig K., Baraniskin A., Holzmann A., Décard B.F., Thum T. Regulated microRNAs in the CSF of patients with multiple sclerosis. A case-control study. Neurology 2012, 79:2166-2170.
119. Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011, 10:745-758.
120. Zhou Y., Simpson S., Holloway A.F., Charlesworth J., van der Mei I., Taylor B.V. The potential role of epigenetic modifications in the heritability of multiple sclerosis. Mult Scler 2014, 20:135-140.
121. Sawcer S., Franklin R.J.M., Ban M. Multiple sclerosis genetics. Lancet Neurol 2014, 13:700-709.
122. Zhang Z., Zhang R. Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. Autoimmun Rev 2015, [in press].
123. Qureshi I.A., Mehler M.F. Developing epigenetic diagnostics and therapeutics for brain disorders. Trends Mol Med 2013, 19:732-741.
124. Ilyas A.A., Chen Z.-W., Cook S.D. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2003, 139:76-80.
125. Brennan K.M., Galban-Horcajo F., Rinaldi S., O'Leary C.P., Goodyear C.S., Kalna G., et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol 2011, 238:87-95.
126. Kasai N., Pachner A.R., Yu R.K. Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 1986, 75:33-42.
127. Nilsson P., Larsson E.-M., Maly-Sundgren P., Perfekt R., Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of r.isk factors after 30years of follow-up. J Neurol 2005, 252:396-402.
128. Malmeström C., Andersson B.A., Haghighi S., Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol 2006, 175:176-182.
129. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisäkk P., Ransohoff R.M., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
130. Baraczka K., Nékám K., Pozsonyi T., Szüts I., Ormos G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur J Neurol 2004, 11:37-42.
131. Wen S.-R., Liu G.-J., Feng R.-N., Gong F.-C., Zhong H., Duan S.-R., et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2012, 244:94-96.
132. Börnsen L., Khademi M., Olsson T., Sørensen P.S., Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011, 17:32-42.
133. Braitch M., Nunan R., Niepel G., Edwards L.J., Constantinescu C.S. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 2008, 65:633-635.
134. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991, 325:467-472.
135. Sarchielli P., Greco L., Stipa A., Floridi A., Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002, 132:180-188.
136. Avsar T., Korkmaz D., Tütüncü M., Demirci N.O., Saip S., Kamasak M., et al. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler 2012, 18:1081-1091.
137. Sellebjerg F., Christiansen M., Nielsen P.M., Frederiksen J.L. Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler 1998, 4:475-479.
138. Brettschneider J., Petzold A., Junker A., Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006, 12:143-148.
139. Guimarães J., Cardoso M.J., Sá M.J. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006, 12:354-356.
140. Massaro A.R. Are there indicators of remyelination in blood or CSF of multiple sclerosis patients?. Mult Scler 1998, 4:228-231.
141. Mitosek-Szewczyk K., Stelmasiak Z., Bartosik-Psujek H., Belniak E. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand 2010, 122:409-413.
142. Rieckmann P., Altenhofen B., Riegel A., Baudewig J., Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997, 41:326-333.
143. Stoop M.P., Singh V., Dekker L.J., Titulaer M.K., Stingl C., Burgers P.C., et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5:e12442.
144. Gillett A., Thessen Hedreul M., Khademi M., Espinosa A., Beyeen A.D., Jagodic M., et al. Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis. Mult Scler 2010, 16:1056-1065.